Disclosed are analogs of human leukocyte interferon which predominantly include those amino acid residues which are common to all naturally-occurring human leukocyte interferon subtype amino acid sequences and which include, at one or more of those positions where there is no amino acid common to all subtypes, an amino acid which predominantly occurs at that position and in no event include any amino acid residue which is not extant in that position in at least one naturally-occurring subtype.
This is a division of application Ser. No. 07/099,096, filed Sep. 21, 1987, now U.S. Pat. No. 4,897,471, which is a continuation application of Ser. No. 06/560,495, filed Dec. 12, 1983, now U.S. Pat. No. 4,695,623, in turn a division of Ser. No. 06/483,451, filed Apr. 13, 1983, in turn a continuation-in-part of application Ser. No. 375,494, filed May 6, 1982, now abandoned.
The present invention encompasses methods for preventing and treating multiple sclerosis by administering to patients in need thereof a therapeutically effective amount of IFN-con in combination with IL-1ra.
The present invention broadly relates to chemical modification of biologically active proteins or analogs thereof. More specifically, the present invention describes novel methods for site-specific chemical modification of various proteins, and resultant compositions having improved biocompatibility and bioactivity.
The present invention broadly relates to chemical modification of biologically active proteins or analogs thereof. More specifically, the present invention describes novel methods for site-specific chemical modification of various proteins, and resultant compositions having improved biocompatibility and bioactivity.
The present invention broadly relates to chemical modification of biologically active proteins or analogs thereof. More specifically, the present invention describes novel methods for site-specific chemical modification of various proteins, and resultant compositions having improved biocompatibility and bioactivity.
The present invention relates to the preparation of polyol/thickened oil suspensions containing a biologically active agent, for the sustained delivery of the biologically active agent. The described protein/glycerol/oil suspensions show sustained release of protein, e.g., G-CSF, of up to at least one week.
